ALSO NOTED: Cardiome awaits FDA decision; Congress to investigate Vytorin scandal; and much more...

> Cardiome is awaiting a critical FDA decision on its drug vernakalant. Report

> It seems that many black U.S. residents are less likely to participate in clinical studies, possibly due to distrust of physicians and fears that they might be harmed by participation, according to a study published in the journal Medicine. Report

> Amgen, you're being served. The New Jersey Attorney General has sent out a subpoena to the California company, asking for "a comprehensive array of documents and information" related to Enbrel sales and marketing. Report

> The deadline bell has rung. At final count, more than 50,000 Vioxx plaintiffs have registered for the $4.85 billion settlement. Report

> Congress is promising hearings on the Vytorin controversy. Report

And Finally... What's in a name? Drug-naming experts are charging hundreds of thousands for just the right combinations of vowels and consonants. Report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.